|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Simonetti RG, Cammà C, Fiorello F, Politi
F, D'Amico G and Pagliaro L: Hepatocellular carcinoma. A worldwide
problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hwang S, Lee SG, Ko GY, Kim BS, Sung KB,
Kim MH, Lee SK and Hong HN: Sequential preoperative ipsilateral
hepatic vein embolization after portal vein embolization to induce
further liver regeneration in patients with hepatobiliary
malignancy. Ann Surg. 249:608–616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ribero D, Abdalla EK, Madoff DC, Donadon
M, Loyer EM and Vauthey JN: Portal vein embolization before major
hepatectomy and its effects on regeneration, resectability and
outcome. Br J Surg. 94:1386–1394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lencioni R: Loco-regional treatment of
hepatocellular carcinoma. Hepatology. 52:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Real MI, Montana X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al:
Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: A
randomised controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu HC, Shan EB, Zhou L, Jin H, Cui PY,
Tan Y and Lu YM: Combination of percutaneous radiofrequency
ablation with transarterial chemoembolization for hepatocellular
carcinoma: Observation of clinical effects. Chin J Cancer Res.
26:471–477. 2014.PubMed/NCBI
|
|
9
|
European Association For The Study Of The
Liver1; European Organisation For Research And Treatment Of Cancer,
. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu HC, Cheng JS, Lai KH, Lin CP, Lo GH,
Lin CK, Hsu PI, Chan HH, Lo CC, Tsai WL and Chen WC: Factors for
early tumor recurrence of single small hepatocellular carcinoma
after percutaneous radiofrequency ablation therapy. World J
Gastroenterol. 11:1439–1444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liao GS, Yu CY, Shih ML, Chan DC, Liu YC,
Yu JC, Chen TW and Hsieh CB: Radiofrequency ablation after
transarterial embolization as therapy for patients with
unresectable hepatocellular carcinoma. Eur J Surg Oncol. 34:61–66.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan S, Xu D and Sun B: Combination of
radiofrequency ablation with transarterial chemoembolization for
hepatocellular carcinoma: A meta-analysis. Dig Dis Sci.
58:2107–2113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koh PS, Chan AC, Cheung TT, Chok KS, Dai
WC, Poon RT and Lo CM: Efficacy of radiofrequency ablation compared
with transarterial chemoembolization for the treatment of recurrent
hepatocellular carcinoma: A comparative survival analysis. HPB
(Oxford). Oct 16–2015.(Epub ahead of print). View Article : Google Scholar
|
|
14
|
Tang C, Shen J, Feng W, Bao Y, Dong X, Dai
Y, Zheng Y and Zhang J: Combination therapy of radiofrequency
ablation and transarterial chemoembolization for unresectable
hepatocellular carcinoma: A retrospective study. Medicine
(Baltimore). 95:e37542016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kokudo N, Hasegawa K, Akahane M, Igaki H,
Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al:
Evidence-based clinical practice guidelines for hepatocellular
carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC
Guidelines). Hepatol Res. 45:2015. View Article : Google Scholar
|
|
16
|
Nishiofuku H, Tanaka T, Matsuoka M, Otsuji
T, Anai H, Sueyoshi S, Inaba Y, Koyama F, Sho M, Nakajima Y and
Kichikawa K: Transcatheter arterial chemoembolization using
cisplatin powder mixed with degradable starch microspheres for
colorectal liver metastases after FOLFOX failure: Results of a
phase I/II study. J Vasc Interv Radiol. 24:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bilehjani E and Fakhari S: Using central
venous catheter for suprapubic catheterization in cardiac surgery.
Res Rep Urol. 9:1–4. 2017.PubMed/NCBI
|
|
18
|
Padhani AR and Ollivier L: The RECIST
(Response Evaluation Criteria in Solid Tumors) criteria:
Implications for diagnostic radiologists. Br J Radiol. 74:983–986.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pagliaro L: MELD: The end of Child-Pugh
classification? J Hepatol. 36:141–142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jansen MC, van Hillegersberg R, Chamuleau
RA, van Delden OM, Gouma DJ and van Gulik TM: Outcome of regional
and local ablative therapies for hepatocellular carcinoma: A
collective review. Eur J Surg Oncol. 31:331–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita Y, Torashima M, Oguni T,
Yamamoto A, Harada M, Miyazaki T and Takahashi M: Liver parenchymal
changes after transcatheter arterial embolization therapy for
hepatoma: CT evaluation. Abdom Imaging. 18:352–356. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Groupe d'Etude et de Traitement du
Carcinome Hépatocellulaire: A comparison of lipiodol
chemoembolization and conservative treatment for unresectable
hepatocellular carcinoma. N Engl J Med. 332:1256–1261. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Hu Y, Ren M, Lu X, Lu G and He S:
Efficacy and safety of radiofrequency ablation combined with
transcatheter arterial chemoembolization for hepatocellular
carcinomas compared with radiofrequency ablation alone: A
time-to-event meta-analysis. Korean J Radiol. 17:93–102. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo W, He X, Li Z and Li Y: Combination of
transarterial chemoembolization (TACE) and radiofrequency ablation
(RFA) vs. surgical resection (SR) on survival outcome of early
hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology.
62:710–714. 2015.PubMed/NCBI
|
|
26
|
Chen QW, Ying HF, Gao S, Shen YH, Meng ZQ,
Chen H, Chen Z and Teng WJ: Radiofrequency ablation plus
chemoembolization versus radiofrequency ablation alone for
hepatocellular carcinoma: A systematic review and meta-analysis.
Clin Res Hepatol Gastroenterol. 40:309–314. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin YJ, Chung YH, Kim JA, Park W, Lee D,
Shim JH, Lee D, Kim KM, Lim YS, Lee HC, et al: Predisposing factors
of hepatocellular carcinoma recurrence following complete remission
in response to transarterial chemoembolization. Dig Dis Sci.
58:1758–1765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kinugasa H, Nouso K, Takeuchi Y, Yasunaka
T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F,
et al: Risk factors for recurrence after transarterial
chemoembolization for early-stage hepatocellular carcinoma. J
Gastroenterol. 47:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jeong SO, Kim EB, Jeong SW, Jang JY, Lee
SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, et al: Predictive
factors for complete response and recurrence after transarterial
chemoembolization in hepatocellular carcinoma. Gut Liver.
11:409–416. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park W, Chung YH, Kim JA, Jin YJ, Lee D,
Shim JH, Lee D, Kim KM, Lim YS, Lee HC, et al: Recurrences of
hepatocellular carcinoma following complete remission by
transarterial chemoembolization or radiofrequency therapy: Focused
on the recurrence patterns. Hepatol Res. 43:1304–1312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Colecchia A, Schiumerini R, Cucchetti A,
Cescon M, Taddia M, Marasco G and Festi D: Prognostic factors for
hepatocellular carcinoma recurrence. World J Gastroenterol.
20:5935–5950. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee JK, Chung YH, Song BC, Shin JW, Choi
WB, Yang SH, Yoon HK, Sung KB, Lee YS and Suh DJ: Recurrences of
hepatocellular carcinoma following initial remission by
transcatheter arterial chemoembolization. J Gastroenterol Hepatol.
17:52–58. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matsuda M, Omata F, Fuwa S, Saida Y,
Suzuki S, Uemura M, Ishii N, Iizuka Y, Fukuda K and Fujita Y:
Prognosis of patients with hepatocellular carcinoma treated solely
with transcatheter arterial chemoembolization: Risk factors for
one-year recurrence and two-year mortality (preliminary data).
Intern Med. 52:847–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rou WS, Lee BS, Moon HS, Lee ES, Kim SH
and Lee HY: Risk factors and therapeutic results of early local
recurrence after transcatheter arterial chemoembolization. World J
Gastroenterol. 20:6995–7004. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsumura H, Nirei K, Nakamura H, Higuchi
T, Arakawa Y, Ogawa M, Tanaka N and Moriyama M: Histopathology of
type C liver disease for determining hepatocellular carcinoma risk
factors. World J Gastroenterol. 19:4887–4896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Paradis V: Histopathology of
hepatocellular carcinoma. Recent Results Cancer Res. 190:21–32.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stefanini GF, Amorati P, Biselli M, Mucci
F, Celi A, Arienti V, Roversi R, Rossi C, Re G and Gasbarrini G:
Efficacy of transarterial targeted treatments on survival of
patients with hepatocellular carcinoma. An Italian experience.
Cancer. 75:2427–2434. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kwan SW, Fidelman N, Ma E, Kerlan RK Jr
and Yao FY: Imaging predictors of the response to transarterial
chemoembolization in patients with hepatocellular carcinoma: A
radiological-pathological correlation. Liver Transpl. 18:727–736.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sugimori K, Nozawa A, Morimoto M, Shirato
K, Kokawa A, Saito T, Numata K and Tanaka K: Extension of
radiofrequency ablation of the liver by transcatheter arterial
embolization with iodized oil and gelatin sponge: Results in a pig
model. J Vasc Interv Radiol. 16:849–856. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Seki T, Tamai T, Nakagawa T, Imamura M,
Nishimura A, Yamashiki N, Ikeda K and Inoue K: Combination therapy
with transcatheter arterial chemoembolization and percutaneous
microwave coagulation therapy for hepatocellular carcinoma. Cancer.
89:1245–1251. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chang NK, Shin SS, Kim JW, Kim HJ, Jeong
YY, Heo SH, Kim JK and Kang HK: Effect of ultrasound-guided
radiofrequency ablation in incompletely treated hepatocellular
carcinoma after transcatheter arterial chemoembolization. Korean J
Radiol. 13 Suppl 1:S104–S111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xie H, Wang H, An W, Ma W, Qi R, Yang B,
Liu C, Gao Y, Xu B and Wang W: The efficacy of radiofrequency
ablation combined with transcatheter arterial chemoembolization for
primary hepatocellular carcinoma in a cohort of 487 patients. PLoS
One. 9:e890812014. View Article : Google Scholar : PubMed/NCBI
|
